Filtered By:
Countries: Israel Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 143 results found since Jan 2013.

Hidden Scars from Breast Cancer
Yes there are lots of hidden scars in breast cancer. I have discussed the emotional side a lot - which boils down to PTSD for some. But there is also the physical side. Every time you look at your body and see your cancer scars, you are reminded of  your cancer misadventure. Its only a scar that will fade over time but its still there.Back in 1984, I found my first breast lump. Due to the limitations of surgery at the time, I had to have an excisional biopsy. And because of my medical history (three years after thyroid cancer) they had to be sure. (And if you are trying to calculate my age, I am still only 37). So I h...
Source: Caroline's Breast Cancer Blog - March 6, 2018 Category: Cancer & Oncology Tags: breast cancer treatment lumpectomy progress scars surgery Source Type: blogs

An emerging treatment option for men with recurring prostate cancer after radiation therapy
Prostate cancer is often a multifocal disease, meaning that several tumors can be present in different parts of gland at the same time. Not all of these tumors are equally problematic, however. And it’s increasingly thought that the tumor with the most aggressive features — called the index lesion — dictates how a man’s cancer is likely to behave overall. That concept has given rise to a new treatment option. Called partial gland ablation (PGA), and also focal therapy, it entails treating only the index lesion and its surrounding tissues, instead of removing the prostate surgically or treating the whole gla...
Source: Harvard Health Blog - April 2, 2021 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs

About that Cancer Moonshot
By KIM BELLARD Joe Biden hates cancer.  He led the Cancer Moonshot in the Obama Administration, and, as President, he reignited it, vowing to cut death rates in half over the next 25 years.  Last month, on the 60th anniversary of President Kennedy’s historic call for an actual moonshot, he vowed “to end cancer as we know it. And even cure cancers once and for all.” But, as several recent studies show, cancer is still surprising us.  ————— Our body has its own defenses against cancer, such as T-cells, and great strides have been made in cancer therapies, includi...
Source: The Health Care Blog - October 6, 2022 Category: Consumer Health News Authors: matthew holt Tags: Health Policy Public Health Biden Cancer Cancer Moonshot Source Type: blogs

About That Cancer Moonshot
BY KIM BELLARD Joe Biden hates cancer.  He led the Cancer Moonshot in the Obama Administration, and, as President, he reignited it, vowing to cut death rates in half over the next 25 years.  Last month, on the 60th anniversary of President Kennedy’s historic call for an actual moonshot, he vowed “to end cancer as we know it. And even cure cancers once and for all.” But, as several recent studies show, cancer is still surprising us.   ————— Our body has its own defenses against cancer, such as T-cells, and great strides have been made in cancer therapies, including ...
Source: The Health Care Blog - October 6, 2022 Category: Consumer Health News Authors: Ryan Bose-Roy Tags: Health Policy Research Cancer Cancer Progression Fungi John F. Kennedy Moonshot Source Type: blogs

Combination hormonal therapy boosts survival in men with aggressive prostate cancer
A standard approach for treating aggressive prostate cancer is to give therapies that block testosterone, a tumor-stimulating hormone. Should initial hormonal therapies fail, doctors can switch to other drugs that suppress testosterone in different ways. One of them, a drug called abiraterone, has been shown to significantly extend lifespans in men who have become resistant to other hormonal treatments. But in June, two major studies reported simultaneously that abiraterone also prolongs life in men with aggressive prostate cancer that’s been newly diagnosed. One of the studies, a phase 3 clinical trial called LATITUDE, ...
Source: Harvard Health Blog - August 18, 2017 Category: Consumer Health News Authors: Charlie Schmidt Tags: Cancer Health Men's Health Prostate Health Source Type: blogs

Newer drugs are improving survival for men with metastatic prostate cancer
This study provides important information that men with advanced forms of prostate cancer are now living longer than they once did, sometimes years longer. Those of us who have been treating prostate cancer for decades appreciate this study’s fundamental finding that the improved longevity from newer cancer drugs is considerable.” The post Newer drugs are improving survival for men with metastatic prostate cancer appeared first on Harvard Health Blog.
Source: Harvard Health Blog - January 31, 2018 Category: Consumer Health News Authors: Charlie Schmidt Tags: Cancer Health Men's Health Prostate Health Source Type: blogs

FDA approves new drug for men at high risk of prostate cancer spread
A newly approved drug called apalutamide is giving hope to thousands of men confronting a tenacious problem after being treated for prostate cancer. Prostate-specific antigen (PSA) levels should plummet to zero after surgery, and to near zero after radiation therapy, but in some men, they continue rising even when there’s no other evidence of cancer in the body. Doctors typically respond to spiking PSA with drugs that block the production of testosterone, which is the male sex hormone that fuels prostate cancer. However, this type of medically induced castration, called hormonal therapy, doesn’t always reduce PSA. More...
Source: Harvard Health Blog - March 15, 2018 Category: Consumer Health News Authors: Charlie Schmidt Tags: Cancer Health Men's Health Prostate Health Source Type: blogs

A mix of treatments may extend life for men with aggressive prostate cancer
For men diagnosed with aggressive cancer that’s confined to the prostate and nearby tissues, the overarching goal of treatment is to keep the disease from spreading (or metastasizing) in the body. Doctors can treat these men with localized therapies, such as surgery and different types of radiation that target the prostate directly. And they can also give systemic treatments that kill off rogue cancer cells in the bloodstream. Hormonal therapy, for instance, is a systemic treatment that kills prostate cancer cells by depriving them of testosterone, which fuels their growth. Now a new study shows that a mix of different t...
Source: Harvard Health Blog - March 31, 2018 Category: Consumer Health News Authors: Charlie Schmidt Tags: Cancer Men's Health Prostate Health Source Type: blogs

New blood test may someday help guide the best treatment for aggressive prostate cancer
Tumors that spread, or metastasize, in the body shed cells into blood that doctors can scrutinize for insights into what a patient’s cancer might do. Analyzing these so-called circulating tumor cells (CTCs) isn’t part of routine care yet, in part because they’re so hard to pick out of the millions of normal cells in a blood sample. Still, scientists are making progress in this area. And in June, a research team reported that treatment decisions made on the basis of CTC testing had increased lifespans in men with an aggressive type of metastatic prostate cancer. Doctors usually treat metastatic prostate cancer with d...
Source: Harvard Health Blog - August 1, 2018 Category: Consumer Health News Authors: Charlie Schmidt Tags: Cancer Health Men's Health Prostate Health Source Type: blogs

Hormonal therapy for aggressive prostate cancer: How long is enough?
This study reaffirms what many clinicians have put into practice: longer duration hormonal therapy in appropriately selected patient populations provides a greater benefit,” said Dr. Marc Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of HarvardProstateKnowledge.org. “Prior studies using three years of hormonal therapy have also shown this, but it is important to recognize that some men may have significantly delayed return of the body’s testosterone upon completion of the therapy — a fact that needs to be discussed when con...
Source: Harvard Health Blog - January 28, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs

Darolutamide approved for nonmetastatic castration-resistant prostate cancer
Sometimes after finishing prostate cancer treatment, men get an unwelcome surprise: their prostate-specific antigen (PSA) levels creep higher, suggesting tumors too small to be seen lurk somewhere in the body. This leads to several options. Doctors can continue to monitor a man’s condition with imaging scans. Or, given the anxiety associated with rising PSA, they might try to lower the levels with chemically “castrating” drugs that inhibit testosterone, a hormone that makes prostate tumors grow faster. Following that treatment, called androgen deprivation therapy (ADT), PSA generally declines and may become undetecta...
Source: Harvard Health Blog - November 22, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Treatments HPK Source Type: blogs

Most men can hold off on radiation after prostate cancer surgery
Decisions about follow-up care after prostate cancer surgery sometimes involve a basic choice. If the cancer had features that predict it could return, doctors will likely recommend radiation therapy. But when should a man get that treatment? Should he get the radiation right away, even if there’s no evidence of cancer in the body (this is called adjuvant radiation)? Or should he opt for “salvage” radiation, which is given only if his blood levels of prostate-specific antigen (PSA) begin to climb? Since prostate cancer cells release PSA, the levels should be nondetectable after surgery. If they increase, that means t...
Source: Harvard Health Blog - December 2, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Treatments HPK Source Type: blogs

African American and white men who receive comparable treatments for prostate cancer have similar survival
Last year, we reported on two studies showing that African American men respond at least as well as white men to prostate cancer treatments given in clinical trials. Nationally, African Americans with prostate cancer are more than twice as likely to die of the disease as their white counterparts, and that has fueled speculation that genetic or biological factors put them at greater risk. But according to this new research, the survival difference disappears when men of either race get the same cutting-edge treatments. Now scientists are reporting that African American and white men with prostate cancer live equally as long...
Source: Harvard Health Blog - February 13, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs

New radiation therapies keep advanced prostate cancer in check
Treatments for prostate cancer are always evolving, and now research is pointing to new ways of treating a cancer that has just begun to spread, or metastasize, after initial surgery or radiation. Doctors usually give hormonal therapies in these cases to block testosterone, which is a hormone that makes the cancer grow faster. But newer evidence shows that treating the metastatic tumors directly with radiation can produce better results. In March, researchers published the latest study that supports this approach. Based at Johns Hopkins University School of Medicine in Baltimore, the team used a method for delivering power...
Source: Harvard Health Blog - April 28, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs

The sequence of hormonal therapy and radiation affects outcomes in men treated for prostate cancer
A common treatment for men with intermediate-risk prostate cancer is to combine radiation with drugs that block testosterone — a hormone that makes the tumors grow faster. (This type of treatment is also called androgen deprivation therapy, or ADT). New research is suggesting the sequence of these treatments may be crucially important. Dr. Dan Spratt, a professor of radiation oncology at the University of Michigan, led the research. He and his colleagues pooled data from two previously published clinical trials (here and here). Taken together, the studies enrolled just over 1,000 men who had been randomly assigned to one...
Source: Harvard Health Blog - November 24, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs